News | April 03, 2022
JBCPL buys Azmarda trademark for India at Rs 246 crore
The brand Azmarda fits well with JBCPL's overall strategy of strengthening its presence in the cardiology segment in India.
The brand Azmarda fits well with JBCPL's overall strategy of strengthening its presence in the cardiology segment in India.
Highlights the need for rebuilding, restructuring, and re-imagining resilient healthcare systems in India
The Cidmus brand shall be affixed on the pharmaceutical composition comprising a combination of Valsartan and Sacubitril (currently under Novartis patent) which is indicated for heart failure patients with reduced ejection fraction
The amalgamation will integrate business operations and provide impetus to the existing portfolio of Alembic
The product will be manufactured at Lupin’s facility in Goa, India
According to IQVIA sales data for the period ending January 2022, Vimpat tablets market achieved annual sales of approx. US $ 1.7 billion
The company plans to launch the product immediately
The tablets are indicated for the treatment of partial-onset seizures in patients 4 years of age and older
Macitentan tablets, 10 mg have an estimated market size of US $ 797 million for twelve months ending Dec 2021 according to IQVIA
Digital meetings driving international partnering at CPhI Japan as companies search for ingredients suppliers
Subscribe To Our Newsletter & Stay Updated
